TICKERNERD
Menu
FATEFATEHealthcare · Biotechnology

FATE Stock Forecast: Fate Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.31
−0.86% on the day

The 11 Wall Street analysts covering Fate Therapeutics, Inc. hold a median 12-month price target of $7 — +203.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$276.8M
Ticker Nerd rank
94 / 100
Median analyst target
$7.00
Analysts covering
11
Revenue$2.1M+9.2% y/y
Operating income−$31.1M
Net income−$30.2M
Free cash flow−$23.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.5%
1M
−15.7%
YTD
+135.7%
1Y
+126.5%
From 52W high
−25.7%
From 52W low
+143.2%
$0.95
$3.11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FATE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Momentum
86
Accruals
81
Issuance
72
Revisions
71
Quality
66
Size
64
Value
58
Volatility
18

Growth (95): Sales and profits are climbing, and climbing faster than before.

Volatility (18): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FATE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FATE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26FATEHigh $8.00Median $7.00Low $2.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
5 Buy6 Hold0 Sell
Low $2.20Median $7.00High $8.00

The green dot is the last close — the median target sits +203.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Piper SandlerReiteratesOverweight$6.00 → $8.00
14 Aug 2026WedbushReiteratesOutperform$7.00
14 Aug 2026Wells FargoMaintainsEqual-Weight$2.50 → $3.50
8 June 2026HC Wainwright & Co.ReiteratesBuy—
8 June 2026HC Wainwright & Co.ReiteratesBuy$7.00
4 May 2026HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.UpgradeBuy—
27 Oct 2025NeedhamReiteratesHold—
27 Oct 2025WedbushUpgradeOutperform—
13 Aug 2025Wells FargoMaintainsEqual-Weight—
12 June 2025NeedhamReiteratesHold—
14 May 2025BairdMaintainsNeutral—
14 May 2025BarclaysMaintainsOverweight—
14 May 2025NeedhamReiteratesHold—
6 Mar 2025NeedhamReiteratesHold—
6 Mar 2025StifelMaintainsHold—
6 Mar 2025WedbushReiteratesNeutral—
6 Mar 2025Wells FargoMaintainsEqual-Weight—
19 Nov 2024NeedhamReiteratesHold—
13 Nov 2024NeedhamReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FATE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FATE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Fate Therapeutics, Inc. returned +126.5% against +17.5% for the S&P 500, dividends included.

FATE vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26FATES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FATE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
2
Fundamentals

Fate Therapeutics, Inc. (FATE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 85% of US stocks

Price / sales
42.6×

Cheaper than 6% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
−1.6×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
9.2%

Higher than 50% of US stocks

Earnings growth (YoY)
9.2%

Higher than 47% of US stocks

Gross margin
—
Operating margin
−1495.4%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−60.8%

Higher than 19% of US stocks

Return on assets
−26.2%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fate Therapeutics, Inc. (FATE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fate Therapeutics, Inc. has a market value of $276.8M and an enterprise value of $198.7M.

  • Revenue in the twelve months to 30 June 2026: $6.5M. The latest quarter grew 9.2% year on year.

  • Net income over the same four quarters: −$126.0M, a −1941.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.05.

  • Free cash flow in the twelve months to 30 June 2026: −$105.7M.

  • Shares outstanding: 116.7M.

  • Trailing P/E: −2.0×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Fate Therapeutics, Inc. employs 161 people — $40K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

FATE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FATEFate Therapeutics, Inc.$276.8M
94
ALXOALX Oncology Holdings, Inc.$268.3M
62
PYXSPyxis Oncology, Inc.$267.7M
80
CAMPCAMP4 Therapeutics Corp.$266.7M
65
ACIUAC Immune SA$273.1M
35
TRDAEntrada Therapeutics, Inc.$264.0M
54
IMRXImmuneering Corp.$275.7M
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FATE news & analysis

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

GlobeNewsWire · 9 Sept 2026positive

Fate Therapeutics announced that clinical data for its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data for its anti-CD19/CD38 candidate FT839, will be presented at the CCR – West 2026 meeting in Huntington Beach, CA from September 17-20, 2026.

Why it matters — A FATE watcher would care because the company is expanding visibility of its iPSC-derived CAR T-cell pipeline (including autoimmune disease applications) at a major rheumatology conference.

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Fate Therapeutics announced that its management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York. The clinical-stage biopharmaceutical company develops iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.

Why it matters — The conference appearance gives FATE watchers an opportunity to hear directly from management about the company's iPSC-derived immunotherapy pipeline.

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

Seeking Alpha · 2 Sept 2026positive

Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the first patient in an outpatient setting. The company plans to open 20 trial sites by the end of 2026 and expects interim analysis data from multiple patients in H2 2027, with earlier phase 1 data showing reductions in disease activity in systemic lupus erythematosus.

Why it matters — This clinical progress on FT819 in lupus nephritis advances a potentially important pipeline candidate for FATE and provides a catalyst timeline for investors to watch.

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewsWire · 14 Aug 2026positive

Fate Therapeutics has initiated the potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, and multiple patients are in the process of screening at several activated sites.

Why it matters — For a FATE watcher, advancing FT819 into a potentially registrational trial marks a significant clinical milestone for the company's lupus nephritis program.

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

Fate Therapeutics reported a Q2 loss of $0.25 per share, narrower than both the Zacks Consensus Estimate of a $0.28 loss and the $0.29 loss from a year ago. Revenue also topped estimates.

Why it matters — The smaller-than-expected quarterly loss and revenue beat suggest the company's financial performance is improving relative to analyst expectations and the prior year.

FAQ

Frequently asked questions about FATE stock

What is the FATE stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Fate Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $2.2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FATE stock a buy right now?

Of the 11 analysts covering Fate Therapeutics, Inc., 5 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fate Therapeutics, Inc. 94 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FATE?

As at 12 Sept 2026, Fate Therapeutics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will FATE stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +203.0% from the last close, and Ticker Nerd's factor model ranks Fate Therapeutics, Inc. 94 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FATE stock forecast for 2030?

No analyst covering Fate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FATE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.2 to $8 over the next 12 months.

How has FATE stock performed over the past year?

Fate Therapeutics, Inc. returned +126.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fate Therapeutics, Inc. do?

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases.

What is the latest news on FATE?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting". Fate Therapeutics announced that clinical data for its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data for its anti-CD19/CD38 candidate FT839, will be presented at the CCR – West 2026 meeting in Huntington Beach, CA from September 17-20, 2026.

Company

About Fate Therapeutics, Inc.

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing. Its portfolio centers on immuno-oncology and immuno-regulatory applications, with product candidates aimed at treating solid tumors, blood cancers, and autoimmune disorders. Fate Therapeutics also applies its cell programming approach to engineer synthetic controls of cell function and produce renewable master cell lines for scalable development. Headquartered in San Diego, California, Fate Therapeutics plays a specialized role in the advanced cell therapy market, where it supports the transition from donor-derived treatments to more standardized, engineered therapeutic products.

CEO Dr. Bahram Valamehr M.B.A., Ph.D. · 161 employees · United States · https://www.fatetherapeutics.com